Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an update.
China Resources Pharmaceutical Group Ltd. has announced the composition of its board of directors and their respective roles within the organization. This announcement is significant as it outlines the leadership structure, which is crucial for the company’s strategic direction and governance, potentially impacting its operational efficiency and stakeholder confidence.
The most recent analyst rating on (HK:3320) stock is a Buy with a HK$7.50 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Ltd. operates in the pharmaceutical industry, focusing on the development, manufacturing, and distribution of pharmaceutical products. The company is positioned in the market as a key player in providing healthcare solutions.
Average Trading Volume: 12,295,656
Technical Sentiment Signal: Sell
Current Market Cap: HK$32.23B
For a thorough assessment of 3320 stock, go to TipRanks’ Stock Analysis page.